Form 8-K - Current report:
SEC Accession No. 0001193125-23-184748
Filing Date
2023-07-10
Accepted
2023-07-10 17:06:29
Documents
12
Period of Report
2023-07-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d443448d8k.htm   iXBRL 8-K 31091
  Complete submission text file 0001193125-23-184748.txt   155225

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fulc-20230705.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20230705_lab.xml EX-101.LAB 17978
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20230705_pre.xml EX-101.PRE 11262
6 EXTRACTED XBRL INSTANCE DOCUMENT d443448d8k_htm.xml XML 3348
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 231080489
SIC: 2834 Pharmaceutical Preparations